Business model and strategy

Initiator´s strategy is to identify promising drug candidates in late preclinical and early clinical development that target medical symptoms with clearly defined unmet medical needs and with attractive commercial opportunities, and rapidly progress these candidates through clinical Proof-of-Concept studies to the point where we expect to enter partnerships for late-stage clinical development. The company aims to commercialise its research efforts through the following two business models:

By internal development of selected programs through the early phases of drug development before out-licensing to pharmaceutical companies who will continue the further clinical development of Initiator’s programs and typical with upfront payments, milestone and royalty payments on product sales to Initiator.

Through early stage research and development collaboration with pharmaceutical companies who will fund the research and development activities and pay upfront, milestones and royalty payments on product sales to Initiator.